SMAD7过表达提升EGFR靶向CAR-T细胞抗非小细胞肺癌功能
该研究通过慢病毒载体构建了EGFR-CAR-T、EGFR-DNR-CAR-T和EGFR-SMAD7-CAR-T三种细胞,在A549肺癌细胞共培养及荷瘤小鼠模型中比较其功能。结果显示EGFR-SMAD7-CAR-T与EGFR-DNR-CAR-T的增殖和裂解能力均优于传统EGFR-CAR-T,且在体内第20天实现肿瘤完全消退,而传统CAR-T仅部分有效。
要点
- SMAD7过表达可增强EGFR-CAR-T抗NSCLC效力并抵抗TGFβ负调控。
- EGFR-SMAD7-CAR-T与EGFR-DNR-CAR-T疗效相当,且无系统性TGFβ抑制效应。
- 体内实验中EGFR-SMAD7-CAR-T使A549荷瘤小鼠肿瘤完全消退。
核心结论
- EGFR-SMAD7-CAR-T对非小细胞肺癌具有高效抗肿瘤活性且能抵抗TGFβ负调控。
研究设计与样本
- 研究构建了EGFR-CAR-T、EGFR-DNR-CAR-T和EGFR-SMAD7-CAR-T三种人T细胞,在A549细胞共培养及荷瘤小鼠模型中评估功能。
主要发现
- EGFR-DNR-CAR-T和EGFR-SMAD7-CAR-T对A549的增殖率和裂解能力均高于传统EGFR-CAR-T。
- TGFβ中和抗体可提高EGFR-CAR-T的性能。
- 体内实验中EGFR-DNR-CAR-T和EGFR-SMAD7-CAR-T在第20天实现肿瘤完全消退,而传统CAR-T仅部分有效。
临床怎么用
- SMAD7过表达策略可能为改善EGFR靶向CAR-T治疗NSCLC提供新思路,但尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Recent advancements in immunotherapy led to the development of Chimeric antigen receptor (CAR) T-cell therapy. CAR-T cell therapy in non-small cell lung cancer (NSCLC) is hindered by overexpression of transforming growth factor (TGFβ) in the cancer cells that have a negative regulatory role on T-cells activity. This study characterized CAR-T with overexpression of mothers against decapentaplegic homologue 7 (SMAD), a negative regulator of TGFβ downstream signalling. METHODS: We have generated three types of CAR-T: epidermal growth factor receptor (EGFR)-CAR-T, EGFR-dominant-negative TGFbeta receptor 2 (DNR)-CAR-T, and EGFR-SMAD7-CAR-T by transducing human T-cells with the lentivirus constructs. We characterized the proliferation, expression of proinflammatory cytokines, activation profile, and lysis capacity in co-cultures with A549 lung carcinoma cells with and without TGFβ neutralizing antibodies. We also tested the therapeutic potential of EGFR-SMAD7-CAR-T in the A549 cells tumour-bearing mice model. RESULTS: Both EGFR-DNR-CAR-T and EGFR-SMAD7-CAR-T demonstrated a higher proliferation rate and lysis capacity to A549 than traditional EGFR-CAR-T. Neutralization of TGFβ by the antibodies resulted in increased performance of EGFR-CAR-T. In vivo, both EGFR-DNR-CAR-T and EGFR-SMAD7-CAR-T resulted in complete tumour resorption by day 20, whereas conventional CAR-T only has a partial effect. CONCLUSION: We demonstrated the high efficacy and resistance to negative TGFβ regulation of EGFR-SMAD7-CAR-T comparable with EGFR-DNR-CAR-T and without the systemic effect of TGFβ inhibition.
引用
- Li G, Liao G, Xie J, et al. Overexpression of SMAD7 improves the function of EGFR-targeted human CAR-T cells against non-small-cell lung cancer. Respirology. 2023. PMID: 37376985. doi:10.1111/resp.14541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。